Sinotherapeutics Inc. (SHA:688247)
China · Delayed Price · Currency is CNY 10.21
+0.43 (4.40%)
At close: Aug 20, 2026
Sinotherapeutics Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,391 | 4,355 | 4,517 | 4,978 | 7,593 | - | |
Market Cap Growth | -22.93% | -3.58% | -9.25% | -34.45% | - | - |
Enterprise Value | 3,614 | 3,590 | 3,769 | 4,194 | 6,771 | - |
Last Close Price | 9.78 | 9.69 | 9.99 | 10.82 | 16.42 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 97.16 | 91.73 | 35.37 | 81.50 | 81.71 | - |
PS Ratio | 10.16 | 9.75 | 8.83 | 16.60 | 30.67 | - |
PB Ratio | 3.36 | 3.37 | 3.55 | 4.11 | 6.45 | - |
P/TBV Ratio | 3.43 | 3.45 | 3.66 | 4.28 | 6.74 | - |
P/FCF Ratio | 113.83 | 81.00 | 127.97 | - | - | - |
P/OCF Ratio | 62.81 | 45.69 | 34.69 | 384.14 | 103.76 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 8.36 | 8.04 | 7.37 | 13.99 | 27.35 | - |
EV/EBITDA Ratio | 67.42 | 59.82 | 26.13 | 62.24 | 80.84 | - |
EV/EBIT Ratio | 129.14 | 103.71 | 31.55 | 94.67 | 116.33 | - |
EV/FCF Ratio | 93.68 | 66.77 | 106.79 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0 | 0 | 0 | 0 | 0.00 | 0.01 |
Debt / EBITDA Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.04 |
Debt / FCF Ratio | 0 | 0 | 0 | - | - | 0.03 |
Net Debt / Equity Ratio | -0.59 | -0.58 | -0.58 | -0.62 | -0.68 | -0.72 |
Net Debt / EBITDA Ratio | -14.52 | -12.44 | -5.08 | -11.11 | -9.62 | -4.18 |
Net Debt / FCF Ratio | -20.15 | -13.88 | -20.78 | 28.81 | 7.81 | -3.91 |
Asset Turnover | 0.30 | 0.31 | 0.36 | 0.22 | 0.23 | 0.39 |
Inventory Turnover | 3.32 | 3.27 | 2.63 | 2.34 | 1.96 | 1.71 |
Quick Ratio | 9.88 | 10.08 | 8.19 | 9.13 | 9.76 | 6.21 |
Current Ratio | 10.98 | 11.27 | 9.46 | 10.49 | 10.59 | 6.91 |
Return on Equity (ROE) | 3.35% | 3.70% | 10.29% | 5.12% | 9.87% | 21.29% |
Return on Assets (ROA) | 1.20% | 1.50% | 5.31% | 2.06% | 3.31% | 7.41% |
Return on Invested Capital (ROIC) | 4.67% | 5.68% | 21.46% | 9.84% | 19.49% | 52.79% |
Return on Capital Employed (ROCE) | 2.00% | 2.60% | 8.80% | 3.50% | 4.70% | 12.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.99% | 1.09% | 2.83% | 1.23% | 1.22% | - |
FCF Yield | 0.88% | 1.23% | 0.78% | -0.52% | -1.36% | - |
Dividend Yield | 0.35% | 0.36% | 0.62% | 0.38% | 0.38% | - |
Payout Ratio | 63.91% | 58.63% | 21.83% | 46.02% | - | - |
Buyback Yield / Dilution | 2.55% | 5.35% | 2.92% | -11.22% | -3.32% | -0.21% |
Total Shareholder Return | 2.89% | 5.71% | 3.54% | -10.84% | -2.94% | -0.21% |